MX387275B - Neoepítopos virales y sus usos - Google Patents

Neoepítopos virales y sus usos

Info

Publication number
MX387275B
MX387275B MX2018004542A MX2018004542A MX387275B MX 387275 B MX387275 B MX 387275B MX 2018004542 A MX2018004542 A MX 2018004542A MX 2018004542 A MX2018004542 A MX 2018004542A MX 387275 B MX387275 B MX 387275B
Authority
MX
Mexico
Prior art keywords
viral
neopipitopes
neoepitopes
antiviral
contemplated
Prior art date
Application number
MX2018004542A
Other languages
English (en)
Other versions
MX2018004542A (es
Inventor
Andrew Nguyen
John Zachary Sanborn
Stephen Charles Benz
Original Assignee
Nantomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics Llc filed Critical Nantomics Llc
Publication of MX2018004542A publication Critical patent/MX2018004542A/es
Publication of MX387275B publication Critical patent/MX387275B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Primary Health Care (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Library & Information Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención se refiere a los tratamientos antivirales/anticáncer contemplados comprenden el análisis de neoepítopos de ADN viral que se ha integrado en el genoma del anfitrión, y el diseño de agentes inmunoterapéuticos contra dichos neoepítopos.
MX2018004542A 2015-10-12 2016-10-12 Neoepítopos virales y sus usos MX387275B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562240471P 2015-10-12 2015-10-12
PCT/US2016/056594 WO2017066290A1 (en) 2015-10-12 2016-10-12 Viral neoepitopes and uses thereof

Publications (2)

Publication Number Publication Date
MX2018004542A MX2018004542A (es) 2018-11-22
MX387275B true MX387275B (es) 2025-03-18

Family

ID=57882798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004542A MX387275B (es) 2015-10-12 2016-10-12 Neoepítopos virales y sus usos

Country Status (9)

Country Link
US (3) US10339274B2 (es)
EP (1) EP3362929B1 (es)
JP (1) JP6991967B2 (es)
KR (1) KR102770755B1 (es)
CN (1) CN108604257B (es)
AU (1) AU2016338947B2 (es)
IL (1) IL258682B (es)
MX (1) MX387275B (es)
WO (1) WO2017066290A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362929B1 (en) 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
US10776966B2 (en) * 2017-04-28 2020-09-15 Oracle International Corporation Graph processing system that allows flexible manipulation of edges and their properties during graph mutation
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
IL280112B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for breast cancer
EP3826669A2 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
US20220108768A1 (en) * 2019-03-08 2022-04-07 Nantomics, Llc System and method for variant calling
KR102425492B1 (ko) * 2020-04-27 2022-07-26 한림대학교 산학협력단 Sars-cov-2 바이러스에 대한 에피토프 기반 펩타이드 백신의 개발 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518569C (en) 2003-03-10 2011-11-15 Expression Pathology, Inc. Liquid tissue preparation from histopathologically processed biological samples, tissues and cells
EP2099826B1 (en) * 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid antibody and uses thereof
JP2012500630A (ja) * 2008-08-22 2012-01-12 ノバルティス アーゲー 肝毒性に関連するｈｌａ対立遺伝子を有していない患者におけるｃｏｘ−２依存性障害を治療するためのｃｏｘ−２阻害剤の使用
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
WO2011149534A2 (en) 2010-05-25 2011-12-01 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
HRP20250981T1 (hr) * 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
JP5564730B2 (ja) * 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
JP6457811B2 (ja) * 2011-09-23 2019-01-23 オックスフォード ナノポール テクノロジーズ リミテッド ポリマー単位を含むポリマーの解析
HUE035207T2 (en) * 2012-01-13 2018-05-02 Univ Wuerzburg J Maximilians Dual antigen-induced bipartite functional complementation
HK1204261A1 (en) * 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP3511425A1 (en) * 2012-07-12 2019-07-17 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
CN103320522B (zh) * 2013-07-16 2016-03-30 深圳华大基因研究院 确定人宫颈癌样本基因组中hpv整合位点的方法和系统
JP2015035212A (ja) * 2013-07-29 2015-02-19 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ターゲットシークエンシングパネルから変異を見つける方法
AU2014324729B2 (en) * 2013-09-26 2019-08-22 Five3 Genomics, Llc Systems, methods, and compositions for viral-associated tumors
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP3090066A4 (en) * 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
CN107847611A (zh) * 2015-05-26 2018-03-27 阿德瓦希斯公司 个性化的基于递送载体的免疫疗法及其用途
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
EP3362929B1 (en) 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof

Also Published As

Publication number Publication date
EP3362929A1 (en) 2018-08-22
EP3362929B1 (en) 2020-08-12
JP2018536225A (ja) 2018-12-06
US12080382B2 (en) 2024-09-03
JP6991967B2 (ja) 2022-01-13
US20190287656A1 (en) 2019-09-19
CA3003304A1 (en) 2017-04-20
AU2016338947B2 (en) 2020-06-04
US20240321392A1 (en) 2024-09-26
AU2016338947A1 (en) 2018-05-10
CN108604257B (zh) 2022-12-13
HK1258093A1 (en) 2019-11-01
EP3362929A4 (en) 2019-06-19
CN108604257A (zh) 2018-09-28
WO2017066290A1 (en) 2017-04-20
KR20180087248A (ko) 2018-08-01
IL258682B (en) 2022-03-01
MX2018004542A (es) 2018-11-22
KR102770755B1 (ko) 2025-02-21
US20170032103A1 (en) 2017-02-02
US10339274B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
MX387275B (es) Neoepítopos virales y sus usos
MX377396B (es) Compuestos de azapiridona y usos de los mismos.
MA46904A (fr) Administration virale de néo-antigènes
CL2018003404A1 (es) Derivados del nucleósido de fosforamidato como agentes anticancer.
EP3368656A4 (en) TARGETED CANCER THERAPY
MX2016011538A (es) Acidos nucleicos antisentido.
NI201700019A (es) Anticuerpos anti tigit
CL2017000564A1 (es) Imitadores de mir-29 y usos de los mismos
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
EP3364949A4 (en) CANCER VACCINES
DOP2022000085A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
SI3198033T1 (sl) Uporaba panelov FGRF-mutantnih genov pri identificiranju rakavih pacientov, ki bodo odzivni na zdravljenje z zaviralcem FGRF
DOP2016000173A (es) Heteroarilos y usos de estos
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
MX2017001279A (es) Usos y composiciones de la flagelina.
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
DK3265102T3 (da) Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
MX377211B (es) Composiciones terapéuticas para usarse en el tratamiento del cáncer.
MX383931B (es) Compuestos de aza-piridona y usos de estos.
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112017006680A2 (pt) variantes de vírus influenza a